Before Revenue

---

Here is a number to hold in your mind while reading everything that follows. The benchmark index of quantum-computing stocks rose 69% in the first five months of 2026, against a gain of about 10.7% for the S&P 500 over the same stretch — a quantum basket outrunning the broad market by nearly seven to one. On a single day in late May, IonQ jumped 10%, D-Wave rocketed 25%, Rigetti soared 24%, and Quantum Computing Inc. leapt 14%, all at once, on no shared news of any commercial substance. The quantum trade, as the headlines put it, "roared back."

Now here is the number to set beside it. The entire global quantum-computing industry — every company, every revenue stream, combined — is forecast to generate roughly $3 billion of annual revenue by 2028. Not profit. Revenue. The combined market value of the handful of pure-play quantum stocks that investors have bid into the stratosphere is many times that figure, for businesses that today produce, among them, a rounding error of actual sales and not one cent of profit. This is a sector whose share prices have detached so completely from its financial reality that the two can be discussed only in different units: the stocks in tens of billions of dollars of market capitalization, the businesses in tens of millions of dollars of revenue.

This essay is about that gap — what fills it, why it has grown so wide, and what it tells you about the late stage of a speculative cycle, when the euphoria that at least clings to real cash flows elsewhere in the market floats free of cash flows altogether and becomes pure narrative. Quantum computing may well be one of the most important technologies of the century. That is not the question. The question is what happens when a genuinely revolutionary science, still years or decades from commercial maturity, collides with a market desperate for the next thing to buy.

The arithmetic of almost nothing

Let us be specific about the revenues, because the specificity is the whole argument, and the bulls would much rather keep the conversation on the vision.

IonQ, the largest and most institutionally respectable of the pure-plays, carries a market capitalization of roughly $20 billion (it has traded between about $19 and $23 billion). Its revenue in the first quarter of 2026 was $64.7 million — a figure it trumpeted as up 755% year over year, a growth rate that sounds miraculous until you remember it is measured off a base near zero, and that a 755% increase on almost nothing is still almost nothing. The company has guided to full-year revenue of $260 to $270 million, which against its valuation implies a price in the range of seventy-five to ninety times sales — for a company running, by its own accounts, a large and ongoing operating loss with no profit in sight.

Rigetti is the detail that should stop a momentum buyer cold. Here is a quantum-computing stock that has participated fully in the sector's euphoria — and whose revenue is going backwards. It reported fourth-quarter 2025 revenue of $1.868 million, missing even the modest consensus by 22%, and full-year revenue of $7.088 million, a 34% decline from the year before. Read that again: a company valued in the billions, in one of the hottest trades of the year, sold less than it had the year prior — about seven million dollars, the revenue of a mid-sized car dealership — and its stock spent much of the year going up anyway. When a stock can rise on a 34% revenue decline, price has stopped having anything to do with the business.

Quantum Computing Inc. — ticker QUBT, and the name alone tells you something about how this sector markets itself — reported first-quarter 2026 revenue of $3.7 million, much of it acquisition-driven, against a fresh net loss, at a price-to-sales multiple reported to be north of 600 times. Six hundred times sales is not a valuation that can be defended on any spreadsheet; it can only be inhabited as a belief. D-Wave, another of the listed quantum names, is expected by analysts to burn through more than $500 million in cash before it turns a profit — a profit that even the most patient forecasts do not pencil in before 2030, if then.

Add it up and the picture is unambiguous. These are pre-revenue, or barely-revenue, companies — one of them shrinking — priced as though the commercial triumph of quantum computing were both certain and imminent, when by every credible technical account it is neither.

The science is real; the stock is a story

It is important to say clearly, because the sector's promoters will accuse any skeptic of denying the science: the science is real, and it is thrilling. Quantum computers exploit the strangest properties of physics — superposition, entanglement — to perform certain classes of calculation that would take conventional machines longer than the age of the universe. Google's Willow chip, unveiled at the end of 2024, demonstrated genuine progress on the central problem of error correction. IBM, Google, Microsoft and a clutch of brilliant startups are making real advances. If and when quantum computing matures, it will transform cryptography, drug discovery, materials science and more. None of that is hype. All of it is plausible. A serious person can believe quantum computing will change the world.

But a chip in a research lab is not a product, and a scientific milestone is not a revenue stream. Willow is a research artifact inside Google's quantum program — not a device you can buy, not a cloud service with a normal product lifecycle, not a thing that generates meaningful sales. The Wall Street Journal's Dan Gallagher noted that the roughly $250 billion that markets briefly tacked onto Alphabet's valuation in the excitement around Willow looked "speculative at best" — and Alphabet is a $2-trillion company with infinite resources and actual products, for which quantum is a rounding error. For the pure-plays, whose entire value rests on a commercial quantum future, the gap between the science and the stock is not a rounding error. It is the whole investment.

This is the defining feature of the quantum trade and the reason it belongs in a category beyond even the richly-valued AI names: in those, however stretched, there is real, enormous, present revenue — Nvidia's two hundred billion dollars, Palantir's seven. In quantum, there is essentially none. The stocks do not trade on earnings, or on sales, or on any financial anchor at all. They trade on narrative — on qubit-count press releases, on milestone announcements, on government-funding headlines, on the momentum of other people buying for the same reason — which is to say they trade on exactly the inputs that drive a stock when there are no fundamentals to drive it instead. It is the purest form of speculation the market currently offers: a wager not on a business but on a someday, priced as a now.

The man who apologized to the stocks

If you want a single moment that captures how unmoored this sector's prices are from anything solid, consider what happened when the most credible voice in computing told the simple truth.

In January 2025, Jensen Huang — the founder of Nvidia, the man whose chips power the actual AI revolution and who has every professional reason to understand the trajectory of advanced computing better than almost anyone alive — was asked about quantum. His answer was measured and, by most expert accounts, entirely reasonable: useful quantum computers, he said, were perhaps fifteen years away "on the early side," and thirty years "on the late side." This is not a hostile assessment. It is a sober one, broadly consistent with what many physicists in the field believe.

The quantum stocks crashed. Billions of dollars of market value evaporated in hours, simply because the man who makes the picks and shovels had publicly estimated that the gold was fifteen to thirty years down the mine. That reaction alone tells you everything: a sector whose valuations cannot survive its own lead technologist stating a realistic timeline is a sector priced for a fantasy timeline. If the stocks were anchored to plausible 2030s cash flows, a "15-to-30-years" comment would be a yawn. That it was a catastrophe reveals what the prices actually embed — imminence, and lots of it.

Then came the part that should trouble anyone watching closely. Two months later, in March 2025, Huang walked the comments back, saying he had been "wrong about the timeline" and that he was surprised his remarks had hurt the stocks. Read that sequence as a forensic matter. The most knowledgeable man in the room gave a realistic estimate; the market punished it violently; and the estimate was then publicly softened, with the explicit acknowledgment that the original truth had "hurt stocks." Whatever the sincere technical merits, the optics are unmistakable: in the quantum trade, even Jensen Huang's realism could not be allowed to stand against the share prices. When reality has to apologize to the ticker, you are no longer in an investment. You are in a mania, and the mania has gotten large enough to discipline the truth.

How a someday gets priced as a now

The mechanics of how this happens are worth laying out, because they recur in every speculative episode and they are operating in textbook form here.

A pre-revenue stock has no earnings to weigh it down and no cash flows to value it by, which sounds like a weakness but in a bull market becomes a strange kind of strength: with no fundamentals to provide gravity, the price can go anywhere the story can carry it. Every qubit-count announcement, every research partnership, every government quantum-initiative headline becomes a catalyst, because there is nothing else for the stock to respond to. Revenue "surprises" of 755% thrill a market that does not stop to notice the base was a few tens of millions. Acquisitions that buy a little revenue are cheered as commercial traction. And because several of these names trade at low nominal share prices and are beloved of retail traders, they move in violent, correlated, options-fueled bursts — the 24%-in-a-day moves, up and down, that have nothing to do with any change in the slow grind of the underlying science. The quantum basket is, functionally, a leveraged bet on enthusiasm about a future, packaged as equity in companies that mostly do not yet have a business.

And the people who understand this best are, predictably, monetizing it. The investment banks have rushed to bring quantum supply to market while the enthusiasm is hot: Honeywell spun out its quantum unit, Quantinuum, into a public listing in June 2026 that raised about $1.68 billion at a sky-high valuation, on the basis of 2025 revenue of roughly $30.9 million against a net loss of $192.6 million — a company losing six dollars for every dollar it earns, sold to the public at a multiple that only makes sense as a bet on a distant future. The IPO window opens, as it always does, when the story is famous enough to sell and before the audience checks the income statement. Insiders and underwriters do not float pre-revenue moonshots at the bottom of enthusiasm. They float them at the top.

The real product is the stock

There is a deeper, less flattering way to understand what these companies actually do for a living, and it is essential to grasp before owning any of them. A business that earns a few million dollars of revenue and loses many multiples of that cannot fund itself from operations — it would run out of cash in months. It survives by doing the one thing its soaring stock price makes easy: selling more stock.

Watch the pattern across the sector. Quantum Computing Inc.'s six-hundred-times-sales valuation came, by its own disclosures, "after similar share issuance" — that is, after printing new shares and selling them into the enthusiasm. IonQ has tapped the market repeatedly. Quantinuum's whole public debut was a capital-raising event, $1.68 billion harvested from investors for a business losing nearly two hundred million a year. This is not incidental to the story; it is the story. For a pre-revenue company, a high share price is not a verdict on the business — it is the business's most important raw material, the thing it converts, through at-the-market offerings and secondary sales, into the cash that keeps the laboratory lights on. The higher the stock goes, the more money the company can raise by diluting its existing holders, which funds another year of operating losses, which buys time for another round of milestone press releases, which lifts the stock, which enables the next raise.

The uncomfortable implication is that for these companies, in their current phase, the product being sold to the public is the stock itself. The quantum computers are the marketing. The retail investor buying a quantum name on a 24%-up day imagines he is funding a race to build a machine; what he is often actually doing is providing the exit liquidity and the operating capital that lets the company issue shares to the next buyer. Dilution is not a risk to the thesis. Dilution is the mechanism by which a cash-burning pre-revenue company stays alive, and it runs directly counter to the interests of the very shareholders whose enthusiasm makes it possible. The science may be a moonshot. The financial engine underneath it is, for now, a treadmill that converts narrative into shares into cash, and asks the crowd to keep feeding it.

We have seen this film

None of this is new, which is the most useful thing about it. The market produces a pre-revenue narrative mania roughly once a cycle, and the script barely changes between productions. In 1999 it was dot-com companies with no earnings and "eyeballs" instead of sales, priced at infinite multiples of revenue that often did not exist. In subsequent cycles it was the genomics stocks after the human genome was sequenced, the 3-D-printing names that were going to remake manufacturing, the cannabis companies, the hydrogen and fuel-cell plays, the metaverse, the SPAC-fuelled electric-vehicle startups with slide decks and no cars. Each was built on a real or plausible technological future. Each attracted a cluster of barely-revenue companies whose stocks detached from any financial anchor and rose on story, momentum and the serial issuance of new shares. And each, without exception, eventually reconnected to reality — not because the underlying technology failed, but because the prices had borrowed a future that arrives, when it arrives at all, far more slowly and to far fewer of the original names than the manic phase assumed. The genome did transform medicine; most of the 2000-era genomics stocks were still wiped out. The lesson is never that the technology was fake. It is that being right about the technology and right about the stock are two completely different problems, and the manic phase systematically confuses them.

Quantum computing fits the template with almost eerie precision: a genuinely revolutionary science, a credible multi-decade future, a small cluster of pre-revenue or barely-revenue companies, valuations in the tens of billions against industry revenue measured in the low billions a half-decade out, violent retail-driven price action, serial share issuance, and a narrative so powerful it forced even Jensen Huang to recant a realistic timeline. We have watched this film before, several times, and we know how the third act goes. The only thing we never know in advance is the precise minute the lights come up.

What the gap is really telling you

None of this is a claim that quantum computing is fake, or that every one of these companies is worthless, or that the technology will not eventually mature into something epochal. It probably will, and one or two of today's names may even be among the winners — the asymmetric, lottery-ticket case for owning a small basket is not unreasonable for an investor who understands they are buying a venture-capital-style bet with a high chance of total loss and a small chance of an enormous payoff. That is an honest way to own these stocks. The dishonest way — the way the market is mostly doing it — is to own them as though the payoff were near and the risk were small, at prices that require a commercial revolution to arrive on a schedule the field's own scientists do not endorse.

Because the deeper signal here is not about quantum computing at all. It is about the market that has bid these stocks up 69% in five months. When a cycle is young and cautious, speculation stays tethered to fundamentals; investors demand earnings, or at least revenue, or at least a credible path to them. When a cycle is late and euphoric, speculation slips its tether and begins to reward pure story — companies with shrinking sales and six-hundred-times-revenue multiples and no profit before the 2030s, rising in violent unison on press releases. The quantum stocks are not the cause of anything. They are a symptom — the thermometer reading at the speculative fringe, where the market reveals, more honestly than it does anywhere else, just how willing it has become to pay a fortune today for a someday it cannot date.

A great technology, real science, brilliant engineers, a transformative long-term future — and prices that have detached from every financial anchor and now float on narrative alone, disciplining even the truth-tellers who try to slow them down. That combination has a name in market history, and the name is not "early." It is the sound a cycle makes near its top, when the money has stopped asking what a company earns and started asking only what it might, someday, become. Quantum computing is probably the future. These stocks, at these prices, are a bet that the future is already here — and the one thing every serious physicist and every honest engineer in the field will tell you is that it is not, not yet, not for years. The science is patient. The share prices are not. That divergence is the entire story, and it resolves, eventually, in only one direction.